ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Top Brokers

More Brokers

Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
AI Sign In Premium IconPremium Help Menu
FTSE 100
8,727.28
1.21%
Dow Jones
44,730.45
-0.32%
Gold vs US Dollar
2,849.635
-0.69%
Brent Oil
74.33
-0.34%
Bitcoin
96,711.62
0.09%
Pepperstone
Advertisement
Registration Strip Icon for alerts Register for real-time alerts, custom portfolio, and market movers
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ
  6. Iterum Therapeutics PLC (ITRM)

  7. Iterum Therapeutics PLC (ITRM) News

Iterum Therapeutics (ITRM)

Iterum Therapeutics PLC
Date:
Sort by:
 Showing the most relevant articles for your search:NASDAQ:ITRM
DateTimeSourceHeadlineSymbolCompany
31/01/202513:00GlobeNewswire Inc.Iterum Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results on February 7, 2025NASDAQ:ITRMIterum Therapeutics PLC
11/12/202411:30Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ITRMIterum Therapeutics PLC
10/12/202412:04Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:ITRMIterum Therapeutics PLC
21/11/202414:15Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ITRMIterum Therapeutics PLC
21/11/202413:30GlobeNewswire Inc.Iterum Therapeutics Regains Full Nasdaq ComplianceNASDAQ:ITRMIterum Therapeutics PLC
14/11/202412:30Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:ITRMIterum Therapeutics PLC
14/11/202412:15Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ITRMIterum Therapeutics PLC
14/11/202412:00GlobeNewswire Inc.Iterum Therapeutics Reports Third Quarter 2024 Financial ResultsNASDAQ:ITRMIterum Therapeutics PLC
11/11/202413:00GlobeNewswire Inc.Iterum Therapeutics to Report Third Quarter 2024 Financial Results on November 14, 2024NASDAQ:ITRMIterum Therapeutics PLC
01/11/202421:10Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ITRMIterum Therapeutics PLC
30/10/202410:24Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:ITRMIterum Therapeutics PLC
28/10/202410:06Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:ITRMIterum Therapeutics PLC
28/10/202409:00PR Newswire (US)Iterum Therapeutics to Host Morning Conference Call on U.S. FDA Approval of ORLYNVAH™ (Oral Sulopenem) for the Treatment of Uncomplicated Urinary Tract InfectionsNASDAQ:ITRMIterum Therapeutics PLC
25/10/202415:20Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ITRMIterum Therapeutics PLC
25/10/202415:03GlobeNewswire Inc.Iterum Therapeutics Receives U.S. FDA Approval of ORLYNVAH™ (Oral Sulopenem) for the Treatment of Uncomplicated Urinary Tract InfectionsNASDAQ:ITRMIterum Therapeutics PLC
15/10/202412:00Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ITRMIterum Therapeutics PLC
11/10/202420:01Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:ITRMIterum Therapeutics PLC
10/10/202412:30GlobeNewswire Inc.Iterum Therapeutics to Present Data at IDWeek 2024NASDAQ:ITRMIterum Therapeutics PLC
09/10/202421:00GlobeNewswire Inc.Iterum Therapeutics to Participate at the 2024 Maxim Healthcare Virtual SummitNASDAQ:ITRMIterum Therapeutics PLC
08/10/202413:15Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ITRMIterum Therapeutics PLC
04/10/202421:20Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ITRMIterum Therapeutics PLC
30/09/202420:15Edgar (US Regulatory)Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) materialNASDAQ:ITRMIterum Therapeutics PLC
30/09/202411:30Edgar (US Regulatory)Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) materialNASDAQ:ITRMIterum Therapeutics PLC
24/09/202413:01Edgar (US Regulatory)Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) materialNASDAQ:ITRMIterum Therapeutics PLC
24/09/202412:59Edgar (US Regulatory)Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) materialNASDAQ:ITRMIterum Therapeutics PLC
23/09/202410:30Edgar (US Regulatory)Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) materialNASDAQ:ITRMIterum Therapeutics PLC
11/09/202420:50Edgar (US Regulatory)Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) materialNASDAQ:ITRMIterum Therapeutics PLC
10/09/202411:00GlobeNewswire Inc.Iterum Therapeutics Provides Update on FDA Advisory Committee Discussion of Oral Sulopenem for the Treatment of uUTI in Adult WomenNASDAQ:ITRMIterum Therapeutics PLC
09/09/202410:15Edgar (US Regulatory)Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) materialNASDAQ:ITRMIterum Therapeutics PLC
06/09/202420:30GlobeNewswire Inc.Iterum Therapeutics to Present at the 26th Annual H.C. Wainwright Global Investment ConferenceNASDAQ:ITRMIterum Therapeutics PLC
 Showing the most relevant articles for your search:NASDAQ:ITRM

Your Recent History

EU
ISBIW
AMUNDI SBIW INAV
BOV
T1RI34M
TripAdvisor
USOTC
DDWWF
Dividend Growth Split (PK)
AMEX
FRDM
Freedom 100 Emerging Mar...
DBI
D4LZ
INAV XTR2 ESG GLAGGSF
Delayed Upgrade Clock
    ADVFN Logo
    InvestorsHub

    United Kingdom
    Company
    Business
    Popular
    Get The App
    App Store
    Google Play

    Support: +44 (0) 203 8794 460 | support@advfn.com

    By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

    © 2025 ADVFN PLC - All Rights Reserved

    Go Ad-Free

    Subscribe to Ad free and enjoy an ad-free experience

    No Ads

    Try Now

    Keep the Ads